{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:59:13Z","timestamp":1781629153645,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Regulation of nuclear pre-mRNA domain containing 1B (RPRD1B, also known as CREPT), has emerged as a potential factor in cancer development. Despite growing evidence, a comprehensive evaluation of RPRD1B across different cancer types has not been conducted. This study aims to explore its prognostic significance in pan-cancer analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Online databases and platforms such as The Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), the Human Protein Atlas (HPA), cBioPortal, TIMER2.0, BioGRID, and SangerBox were used to gather data on RPRD1B across various cancers. The pan-cancer patient datasets were analyzed to explore the relationships among RPRD1B expression, genetic alterations, protein interactions, tumor immunity, and clinical features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The findings indicate that RPRD1B was upregulated in most tumor types compared to normal tissues, and increased protein levels observed in several cancers. Notably, high RPRD1B expression was associated with the infiltration of immune cells, endothelial cells, and cancer-associated fibroblasts (CAFs), as well as the expression of tumor immune markers in certain cancers. Additionally, elevated RPRD1B expression proved useful for aiding cancer diagnosis and predicting prognosis across multiple cancer types. In vitro studies showed that RPRD1B was upregulated in colon adenocarcinoma (COAD) cell lines, where it promoted cell proliferation and invasion. In vivo experiments further demonstrated that knocking down RPRD1B significantly suppressed tumor growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High RPRD1B expression contributes to cancer progression and may function as a key biomarker for the diagnosis and prognosis across various tumor types.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-025-03805-4","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T20:15:35Z","timestamp":1767730535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive pan-cancer analysis of\u00a0RPRD1B as a promising diagnostic and prognostic biomarker"],"prefix":"10.1007","volume":"17","author":[{"given":"Ye","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"4","key":"3805_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465\u201372.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3805_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/clinchem\/hvad202","volume":"70","author":"SM Schwartz","year":"2024","unstructured":"Schwartz SM. Epidemiology of cancer. Clin Chem. 2024;70(1):140\u20139.","journal-title":"Clin Chem"},{"issue":"4","key":"3805_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.20892\/j.issn.2095-3941.2020.0387","volume":"17","author":"D Sun","year":"2020","unstructured":"Sun D, Li H, Cao M, He S, Lei L, Peng J, et al. Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med. 2020;17(4):879\u201395.","journal-title":"Cancer Biol Med"},{"issue":"12","key":"3805_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1177\/00220345211014795","volume":"100","author":"S Warnakulasuriya","year":"2021","unstructured":"Warnakulasuriya S, Kerr AR. Oral cancer screening: past, present, and future. J Dent Res. 2021;100(12):1313\u201320.","journal-title":"J Dent Res"},{"key":"3805_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2021.11.007","volume":"83","author":"WT Rahman","year":"2022","unstructured":"Rahman WT, Helvie MA. Breast cancer screening in average and high-risk women. Best Pract Res Clin Obstet Gynaecol. 2022;83:3\u201314.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"4","key":"3805_CR6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1053\/j.gastro.2020.12.068","volume":"160","author":"AN Burnett-Hartman","year":"2021","unstructured":"Burnett-Hartman AN, Lee JK, Demb J, Gupta S. An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for early-onset colorectal cancer. Gastroenterology. 2021;160(4):1041\u20139.","journal-title":"Gastroenterology"},{"key":"3805_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102973","volume":"138","author":"N Dusetti","year":"2025","unstructured":"Dusetti N, Bachet JB, Chanez B, Neuzillet C, de Mestier L, Williet N, et al. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Cancer Treat Rev. 2025;138:102973.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"3805_CR8","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1039\/C4CS00370E","volume":"44","author":"L Wu","year":"2015","unstructured":"Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44(10):2963\u201397.","journal-title":"Chem Soc Rev"},{"issue":"8","key":"3805_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nsmb.2853","volume":"21","author":"Z Ni","year":"2014","unstructured":"Ni Z, Xu C, Guo X, Hunter GO, Kuznetsova OV, Tempel W, et al. RPRD1A and RPRD1B are human RNA polymerase II C-terminal domain scaffolds for Ser5 dephosphorylation. Nat Struct Mol Biol. 2014;21(8):686\u201395.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"3805_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ccr.2011.12.016","volume":"21","author":"D Lu","year":"2012","unstructured":"Lu D, Wu Y, Wang Y, Ren F, Wang D, Su F, et al. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes. Cancer Cell. 2012;21(1):92\u2013104.","journal-title":"Cancer Cell"},{"issue":"26","key":"3805_CR11","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1038\/s41388-018-0161-z","volume":"37","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wang S, Kang W, Liu C, Dong Y, Ren F, et al. CREPT facilitates colorectal cancer growth through inducing Wnt\/beta-catenin pathway by enhancing p300-mediated beta-catenin acetylation. Oncogene. 2018;37(26):3485\u2013500.","journal-title":"Oncogene"},{"issue":"8","key":"3805_CR12","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41416-021-01269-1","volume":"124","author":"W Zhai","year":"2021","unstructured":"Zhai W, Ye X, Wang Y, Feng Y, Wang Y, Lin Y, et al. CREPT\/RPRD1B promotes tumorigenesis through STAT3-driven gene transcription in a p300-dependent manner. Br J Cancer. 2021;124(8):1437\u201348.","journal-title":"Br J Cancer"},{"issue":"8","key":"3805_CR13","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1093\/nar\/gku160","volume":"42","author":"JC Morales","year":"2014","unstructured":"Morales JC, Richard P, Rommel A, Fattah FJ, Motea EA, Patidar PL, et al. Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair. Nucleic Acids Res. 2014;42(8):4996\u20135006.","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"3805_CR14","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108\u201310.","journal-title":"Cancer Res"},{"issue":"W1","key":"3805_CR15","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360.","journal-title":"Nucleic Acids Res"},{"key":"3805_CR16","doi-asserted-by":"crossref","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.","DOI":"10.1126\/science.1260419"},{"issue":"269","key":"3805_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.","journal-title":"Sci Signal"},{"issue":"5","key":"3805_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cbio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"D1","key":"3805_CR19","doi-asserted-by":"publisher","first-page":"D529","DOI":"10.1093\/nar\/gky1079","volume":"47","author":"R Oughtred","year":"2019","unstructured":"Oughtred R, Stark C, Breitkreutz BJ, Rust J, Boucher L, Chang C, et al. The BioGRID interaction database: 2019 update. Nucleic Acids Res. 2019;47(D1):D529\u201341.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"3805_CR20","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504.","journal-title":"Genome Res"},{"issue":"W1","key":"3805_CR21","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"3805_CR22","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.7150\/thno.53649","volume":"11","author":"J Hu","year":"2021","unstructured":"Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, et al. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021;11(7):3089\u2013108.","journal-title":"Theranostics"},{"issue":"5","key":"3805_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.238","volume":"3","author":"D Chen","year":"2024","unstructured":"Chen D, Xu L, Xing H, Shen W, Song Z, Li H, et al. Sangerbox 2: enhanced functionalities and update for a comprehensive clinical bioinformatics data analysis platform. Imeta. 2024;3(5):e238.","journal-title":"Imeta"},{"key":"3805_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fimmu.2020.00369","volume":"11","author":"E Picard","year":"2020","unstructured":"Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 2020;11:369.","journal-title":"Front Immunol"},{"issue":"10","key":"3805_CR25","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/2326-6066.CIR-19-0149","volume":"7","author":"AM Goodman","year":"2019","unstructured":"Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res. 2019;7(10):1570\u20133.","journal-title":"Cancer Immunol Res"},{"issue":"suppl_12","key":"3805_CR26","doi-asserted-by":"publisher","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","volume":"28","author":"L Li","year":"2017","unstructured":"Li L, Goedegebuure SP, Gillanders WE. Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 2017;28(suppl_12):xii11\u20137.","journal-title":"Ann Oncol"},{"key":"3805_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102016","volume":"86","author":"D Schizas","year":"2020","unstructured":"Schizas D, Charalampakis N, Kole C, Economopoulou P, Koustas E, Gkotsis E, et al. Immunotherapy for pancreatic cancer: a 2020 update. Cancer Treat Rev. 2020;86:102016.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"3805_CR28","first-page":"6596","volume":"7","author":"Y She","year":"2014","unstructured":"She Y, Liang J, Chen L, Qiu Y, Liu N, Zhao X, et al. CREPT expression correlates with poor prognosis in patients with retroperitoneal leiomyosarcoma. Int J Clin Exp Pathol. 2014;7(10):6596\u2013605.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"3805_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijom.2021.03.012","volume":"51","author":"YJ Siril","year":"2022","unstructured":"Siril YJ, Kouketsu A, Saito H, Takahashi T, Kumamoto H. Immunohistochemical expression levels of cyclin D1 and CREPT reflect the course and prognosis in oral precancerous lesions and squamous cell carcinoma. Int J Oral Maxillofac Surg. 2022;51(1):27\u201332.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"3","key":"3805_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.bbrc.2016.10.067","volume":"480","author":"G Zheng","year":"2016","unstructured":"Zheng G, Li W, Zuo B, Guo Z, Xi W, Wei M, et al. High expression of CREPT promotes tumor growth and is correlated with poor prognosis in colorectal cancer. Biochem Biophys Res Commun. 2016;480(3):436\u201342.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"3805_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174309","volume":"12","author":"J Ma","year":"2017","unstructured":"Ma J, Ren Y, Zhang L, Kong X, Wang T, Shi Y, et al. Knocking-down of CREPT prohibits the progression of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc expression. PLoS ONE. 2017;12(4):e0174309.","journal-title":"PLoS ONE"},{"issue":"1","key":"3805_CR32","first-page":"136","volume":"1","author":"Y Fang","year":"2025","unstructured":"Fang Y, Kong Y, Rong G, Luo Q, Liao W, Zeng D. Systematic investigation of tumor microenvironment and antitumor immunity with IOBR. Med Res. 2025;1(1):136\u201340.","journal-title":"Med Res"},{"key":"3805_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mdr2.70004","volume":"1","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhang G, Xu P, Yu F, Li L, Huang R, et al. Optimized dynamic network biomarker deciphers a high-resolution heterogeneity within thyroid cancer molecular subtypes. Med Research. 2025;1:10\u201331.","journal-title":"Med Research"},{"key":"3805_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2021.104189","volume":"138","author":"G Armani","year":"2021","unstructured":"Armani G, Pozzi E, Pagani A, Porta C, Rizzo M, Cicognini D, et al. The heterogeneity of cancer endothelium: the relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment. Microvasc Res. 2021;138:104189.","journal-title":"Microvasc Res"},{"issue":"1","key":"3805_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"key":"3805_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.596798","volume":"11","author":"L Arora","year":"2021","unstructured":"Arora L, Pal D. Remodeling of stromal cells and immune landscape in microenvironment during tumor progression. Front Oncol. 2021;11:596798.","journal-title":"Front Oncol"},{"issue":"3","key":"3805_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41577-025-01140-x","volume":"25","author":"EE McCartney","year":"2025","unstructured":"McCartney EE, Buechler MB. Podoplanin mediates stromal-immune crosstalk in the lymph node. Nat Rev Immunol. 2025;25(3):160.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"3805_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70011","volume":"4","author":"B Ye","year":"2025","unstructured":"Ye B, Fan J, Xue L, Zhuang Y, Luo P, Jiang A, et al. iMLGAM: Integrated machine learning and genetic algorithm-driven multiomics analysis for pan-cancer immunotherapy response prediction. iMeta. 2025;4(2):e70011.","journal-title":"iMeta"},{"issue":"6382","key":"3805_CR39","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"3","key":"3805_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1039\/D4CB00212A","volume":"6","author":"RY Moreno","year":"2025","unstructured":"Moreno RY, Panina SB, Zhang YJ. RPRD1B\u2019s direct interaction with phosphorylated RNA polymerase II regulates polyadenylation of cell cycle genes and drives cancer progression. RSC Chem Biol. 2025;6(3):423\u201337.","journal-title":"RSC Chem Biol"},{"key":"3805_CR41","doi-asserted-by":"crossref","unstructured":"Ali I, Ruiz DG, Ni Z, Johnson JR, Zhang H, Li PC, et al. Crosstalk between RNA Pol II C-terminal domain acetylation and phosphorylation via RPRD Proteins. Mol Cell. 2019;74(6):1164\u201374 e4.","DOI":"10.1016\/j.molcel.2019.04.008"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03805-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03805-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03805-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:12:56Z","timestamp":1781626376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03805-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3805"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03805-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}